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expectations and preferences with self-reported outcomes and
satisfaction. In this report we evaluate the psychometric perfor-
mance of the Migraine Treatment Satisfaction measure (MTS)
using participants from a randomized controlled trial of
headache management. METHODS: Enrolled migraineurs com-
pleted the ﬁrst two modules of the MTS upon enrollment in the
treatment program and the ﬁnal two modules at six-months.
Internal consistency reliability was computed within each of the
four modules. Discriminant validity was ascertained by compar-
ison with the Migraine Disability Assessment Questionnaire
(MIDAS), Patient Health Questionnaire (PHQ-9), and Migraine
Symptom Frequency and Bothersomeness (MSFB) scores. For
convergent validity, Pearson’s correlation was used to measure
associations between MTS scores, general health status (SF-36),
MIDAS and MSFB. RESULTS: Overall, 124 migraineurs (mean
age 45.4 years, 75% women, 54.1% Caucasian) were enrolled.
Internal consistency statistics for the expectations, outcomes,
importance ratings, and satisfaction measures were within
acceptable ranges (0.83, 0.86, 0.85, and 0.95, respectively) and
were consistent with earlier development work for this measure.
Satisfaction (MTS) decreased signiﬁcantly as depression (PHQ-
9 scores) increased. MTS scores by symptom bothersomeness 
tertiles and symptom frequency tertiles showed a signiﬁcant
decrease in satisfaction among those experiencing moderate-
severe symptom bothersomeness and symptom frequency.
Derived MTS scores showed strong associations with MSFB
scores (-0.301; p < 0.01), MIDAS (-0.267; p < 0.01), general
health (0.253; p < 0.05), mental health (0.217; p < 0.05) and
vitality subscales of SF-36 (0.214; p < 0.05). Patients on triptans
reported a signiﬁcantly higher satisfaction compared to patients
on analgesics (39.5 vs. 32.9; p < 0.05). CONCLUSION: MTS
can be considered as a valuable instrument to be used for the
description of migraine treatment satisfaction.
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OBJECTIVES: To develop a patient-reported outcomes data col-
lection system using the internet or the telephone for migraine
patients being treated with Relpax (eletriptan HBr). METHODS:
Physicians provided medication and study information to 
eligible migraine patients in their practice willing to participate.
Patients were able to access the data collection system (The
Relpax Challenge), either via the Internet or an interactive voice
response system (IVR). Patient kits contained preprinted ID
numbers that mapped them to their physicians. Upon enrolling,
migraineurs answered a baseline survey of demographic infor-
mation, migraine experience and associated health care utiliza-
tion, and a prior migraine medication satisfaction survey.
Following the baseline survey, patients were then asked to rate
their satisfaction to treatment for three subsequent Relpax
treated migraine attacks. Data was collected over an SSL pro-
tected website and stored in a SQL server database. The website
was developed using Macromedia and ensured a user-friendly
environment for data entry. The IVR also reposited data into the
same data warehouse. RESULTS: Currently 3604 registered
patients have completed questionnaires for 5837 Relpax treated
attacks. The majority of the respondents were female (87.53%)
with an average age of 37.5 years. Forty-four percent completed
data on all three attacks, of which 93.1% indicated that they
would take Relpax again. Migraineurs were satisﬁed (four or ﬁve
on a ﬁve point scale) with their relief of pain (70.20%), speed of
relief (60.10%), relief of nausea (50.91%), relief of sensitivity to
light (58.10%), relief of sensitivity to sound (57.29%) and their
ability to return to their day (57.29%). CONCLUSIONS: Uti-
lizing this technology, we have created a reliable and easy-to-use
internet and phone based system for collecting patient reported
outcomes. Satisfaction with Relpax treatment as well as other
treatment outcomes were consistent with the results observed in
the Relpax clinical trials.
NEUROLOGICAL DISORDERS—Multiple Sclerosis
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OBJECTIVE: Examine factors that inﬂuence work days missed
among employees diagnosed with multiple sclerosis (MS).
METHODS: This retrospective analysis used a claims database
with inpatient and outpatient visits, prescription drug services,
and time missed from work for the years 1999 through 2002.
Employees with a diagnosis of MS were identiﬁed and examined
over the calendar year of ﬁrst observed diagnosis in the database
(N = 284). Multivariate regressions controlling for demogra-
phic characteristics, overall severity of illness, and type of
immunomodulatory medication examined factors that inﬂuence
days missed from work. RESULTS: Demographic characteristics,
overall severity of illness, and type of immunomodulatory
therapy all impacted time missed from work. Individual comor-
bid diagnoses had no impact on time missed from work. 
Comparing individuals treated with interferon beta-1a (intra-
muscular), interferon beta-1b, or the speciﬁc immunomodulator
glatiramer acetate to those who received no treatment for MS
revealed that only glatiramer acetate was associated with signif-
icantly fewer days missed from work for short term disability
(18.24 fewer days, p = 0.03), worker’s compensation (29.50
fewer days, p = 0.04) or any reason (53.70 fewer days, p =
0.003). Average wage estimates of $22.18i and research that
reveals productivity lost due to absence averages 1.61 times the
wageii suggest an annual productivity savings of $15,340 asso-
ciated with glatiramer acetate. CONCLUSIONS: Demographic
characteristics and overall severity of illness impact time missed
from work for employees diagnosed with MS. Only MS treat-
ment with glatiramer acetate was associated with signiﬁcantly
fewer days of work missed.
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OBJECTIVES: 1) Identify the prevalence of access barriers to
prescription medications among beneﬁciaries with Multiple Scle-
rosis (MS); and 2) estimate the out of pocket price of commonly
used prescription medications among insured and under-insured
MS beneﬁciaries. METHODS: Using claims data from the
Medicare Current Beneﬁciary Survey (MCBS) 1992–2001, we
identiﬁed 156 beneﬁciaries with a diagnosis of multiple sclerosis
on four or more claims (ICD-9 340). The MCBS is an overlap-
ping panel survey linked to associate claims that includes ques-
tions on out-of-pocket price, access, and use of prescription
medications. We estimated the average out-of-pocket price of
prescription medications and prevalence of perceived economic
barriers to address the hypothesis that the expansion of Medicare
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to include an outpatient drug beneﬁt will decrease beneﬁciaries’
burden of multiple sclerosis. RESULTS: Few MS beneﬁciaries
(5%) reported that they did not get prescription medications that
were prescribed for them. Some beneﬁciaries (15%) reported
delaying health care due to the cost. The average out-of-pocket
cost of commonly used medications (e.g., baclofen (Baclofen®),
interferon beta-1B (Betaseron®), and ﬂuoxetine (Prozac®))
among the insured is about half the price borne by the under-
insured beneﬁciaries. For example, interferon beta-1B is $27 per
prescription among insured beneﬁciaries, and $58.50 among
under-insured beneﬁciaries. Similar results were found for other
medications that are common among MS beneﬁciaries. CON-
CLUSIONS: Our ﬁndings suggest that MS beneﬁciaries perceive
few economic barriers to necessary health care, particularly pre-
scription medications. However, we ﬁnd substantial differences
exist in the out-of-pocket price of commonly used medications
between under-insured and insured beneﬁciaries. These differ-
ences should attenuate with the expansion of Medicare to
include a drug beneﬁt decreasing the economic burden of multi-
ple sclerosis.
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OBJECTIVE: To develop a measure of treatment satisfaction
that assesses attributes speciﬁc to injected medications for mul-
tiple sclerosis (MS). METHODS: Item development for the MS
Treatment Satisfaction Questionnaire (MSTCQ) was initiated
with review of MS websites, literature, adverse effects, as well 
as interviews and focus groups with MS patients. Pilot testing
resulted in aggregation of items postulated to assess adverse
effects, difﬁculty of use, inconvenience, and discomforts. The
MSTCQ test instrument included nine items describing “Satis-
faction with the Injection System” and 11 items describing “Side
Effects.” The instrument was completed by 317 patients, ages
18–60 years, who had been using interferon-beta-1a subcuta-
neously for > six-months. RESULTS: The “Satisfaction with the
Injection System” subscale ﬁt a one-component solution with
internal consistency coefﬁcient with good cross-sectional relia-
bility (a = 0.70). A principal components analysis of the 11 items
assessing “Side Effects” resulted in a three-component solution:
ﬂu-like side effects (a = 0.82); injection-site reactions (a = 0.68),
and global items (a = 0.75). Test-retest reliabilities at one-week
(N = 55) were Satisfaction r = 0.68 (intraclass correlation coef-
ﬁcient); Side Effects: ﬂu-like side effects, r = 0.86; global evalu-
ation of side effects, r = 0.77; injection site side effects, r = 0.73.
Almost all correlations were statistically signiﬁcant (p < 0.001).
Correlations with demographic variables showed signiﬁcant
associations with the MSTCQ total and subscale scores. Age,
falling behind in work and home activities, and level of activ-
ity/independence exhibit the most consistent relationships to the
various MSTCQ measures. CONCLUSIONS: The initial devel-
opment and testing shows that the MSTCQ should provide
insight into the concerns of MS patients about their use of
injected medications. These data indicate that older respondents
and respondents who are relatively more active and independent
have a more favorable view of their MS treatment.
NEUROLOGICAL DISORDERS—Other
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OBJECTIVES: Restless Legs Syndrome (RLS) is a sensorimotor
disorder resulting in a desire to move the limbs, which often leads
to severe sleep disturbances. This study aims to compare the
health-related quality of life (HRQOL) burden that RLS places
on US and European (EU) individuals. METHODS: Analyzed
cross-sectional data (with screening, RLS symptom, and SF-36
items) from EU (France, N = 75; Germany, N = 25; Italy, N =
42; Spain, N = 37; UK, N = 44) and US (N = 158) samples. SF-
36 scores of persons with RLS were compared with patient (type-
2 diabetes, depression, osteoarthritis [OA]) and US general
population norms. Regression methods were applied to estimate
sociodemographically adjusted norm values and test for signiﬁ-
cance. Comparisons to norm were conducted: 1) maintaining the
case-mix of conditions that both RLS and general population
respondents presented (“total” burden); 2) statistically adjusting
for conditions not attributed to RLS (“unique” burden). Burden
is deﬁned as a negative deviation in SF-36 scores from norm asso-
ciated with the presence of a medical condition (e.g. RLS).
RESULTS: Relative to an average adult, total burden ranged
from 0.44 to 1.07 standard deviations (SD) below general pop-
ulation norm for US, and 0.49 to 1.04 SD for EU. Relative to
an average healthy adult, the unique burden ranged from 0.63
to 1.36 SD and from 0.91 to 1.48 SD below norm for both US
and EU samples, respectively, (where 0.5 SD is viewed as meeting
standards of minimal clinically important difference). US RLS
sufferers reported the greatest burden on physical domains; EU
on mental health. For both samples, RLS burden was greater
than type-2 diabetes and OA, and similar to depression. CON-
CLUSIONS: RLS places a sizable burden on HRQOL—similar
for US and EU samples, affecting both physical and mental
health. The EU sample is more affected in mental health; the US
sample is more affected in physical health.
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OBJECTIVES: Restless legs syndrome (RLS) is a sensorimotor
disorder characterized by an irresistible urge to move the limbs,
which often results in disturbed sleep. This study aims to con-
textualize the impact of RLS on health-related quality of life
(HRQOL) in terms of functional limitations, mental health and
resource use. METHODS: Cross-sectional data from an omnibus
questionnaire (with screening and RLS symptom items) and the
SF-36 Health Survey (to assess HRQOL) from a US sample of
158 participants with RLS were analyzed. Capitalizing on prior
work that linked external criteria to patients differing in general
health self-evaluations, we assessed SF-36 physical and mental
